A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET-1
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Results of post hoc pooled analysis from three phase 3 trials examining the efficacy of rifaximin in improving bloating presented at the Digestive Disease Week 2018
    • 03 Jun 2018 According to the Salix Pharmaceuticals media release, pooled analysis results from this and other two trials (TARGET-2 and TARGET-3) will be presented at Digestive Disease Week 2018.
    • 27 May 2015 According to a media release, Rifaximin (Xifaxan) 550 mg was approved by US FDA for the treatment of IBS-D in adults based on the data from this and two other phase III trials (TARGET-2, CTP 700027104 and TARGET-3; CTP 700204719 ).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top